Trial Profile
An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Selicrelumab (Primary) ; Vanucizumab (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Roche
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Oct 2019 Planned End Date changed from 9 Jun 2020 to 31 Oct 2019.
- 30 Oct 2019 Planned primary completion date changed from 9 Jun 2020 to 31 Oct 2019.